JP6006404B2 - 抗ＢＬｙＳ抗体 - Google Patents

抗ＢＬｙＳ抗体 Download PDF

Info

Publication number
JP6006404B2
JP6006404B2 JP2015511926A JP2015511926A JP6006404B2 JP 6006404 B2 JP6006404 B2 JP 6006404B2 JP 2015511926 A JP2015511926 A JP 2015511926A JP 2015511926 A JP2015511926 A JP 2015511926A JP 6006404 B2 JP6006404 B2 JP 6006404B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
blys
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015511926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517505A (ja
Inventor
ボー チェン
ボー チェン
フイ フェン
フイ フェン
ホンビン シュー
ホンビン シュー
Original Assignee
ウーハン テラソース バイオサイエンシーズ インコーポレイテッド
ウーハン テラソース バイオサイエンシーズ インコーポレイテッド
シャンハイ ユニオン バイオファーム カンパニー リミテッド
シャンハイ ユニオン バイオファーム カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウーハン テラソース バイオサイエンシーズ インコーポレイテッド, ウーハン テラソース バイオサイエンシーズ インコーポレイテッド, シャンハイ ユニオン バイオファーム カンパニー リミテッド, シャンハイ ユニオン バイオファーム カンパニー リミテッド filed Critical ウーハン テラソース バイオサイエンシーズ インコーポレイテッド
Publication of JP2015517505A publication Critical patent/JP2015517505A/ja
Application granted granted Critical
Publication of JP6006404B2 publication Critical patent/JP6006404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015511926A 2012-05-22 2013-05-22 抗ＢＬｙＳ抗体 Active JP6006404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210160474.3A CN103421113B (zh) 2012-05-22 2012-05-22 抗BLyS抗体
CN201210160474.3 2012-05-22
PCT/CN2013/076074 WO2013174264A1 (zh) 2012-05-22 2013-05-22 抗BLyS抗体

Publications (2)

Publication Number Publication Date
JP2015517505A JP2015517505A (ja) 2015-06-22
JP6006404B2 true JP6006404B2 (ja) 2016-10-12

Family

ID=49623127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511926A Active JP6006404B2 (ja) 2012-05-22 2013-05-22 抗ＢＬｙＳ抗体

Country Status (8)

Country Link
US (1) US9828423B2 (enExample)
EP (2) EP2853543B1 (enExample)
JP (1) JP6006404B2 (enExample)
CN (1) CN103421113B (enExample)
IN (1) IN2014MN02367A (enExample)
RU (1) RU2613422C2 (enExample)
WO (1) WO2013174264A1 (enExample)
ZA (1) ZA201408955B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615672D0 (en) 2006-08-07 2006-09-13 Rencol Tolerance Rings Ltd Assembly of a shaft and a housing assembly
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN104804090B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体和用途
CN104804092B (zh) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及其用途
CN104804091B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及用途
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN104628856A (zh) * 2015-01-23 2015-05-20 中国人民解放军军事医学科学院放射与辐射医学研究所 一种抗BLyS单链抗体及其制备方法和用途
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
CN106916224B (zh) * 2015-12-28 2021-03-23 中国人民解放军军事医学科学院放射与辐射医学研究所 抗b淋巴细胞刺激因子单克隆抗体及其制备方法和用途
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
US20210347873A1 (en) * 2016-07-06 2021-11-11 Shanghai Pharmaexplorer Co., Ltd. Blys antibody, preparation method therefor and application thereof
WO2018157169A1 (en) * 2017-02-27 2018-08-30 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
US12404346B2 (en) 2019-01-31 2025-09-02 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN112111461B (zh) * 2020-08-17 2022-08-30 浙江正熙生物医药有限公司 一种单细胞分选构建单克隆抗体高产株细胞工作库的方法
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
US20240182599A1 (en) * 2022-10-07 2024-06-06 Abwiz Bio, Inc. Anti-ige antibodies
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266439C (en) * 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DK1294769T3 (da) * 2000-06-16 2011-04-26 Human Genome Sciences Inc Antistoffer der immunspecifikt binder til BLyS
AU2002364954A1 (en) 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
CN1168831C (zh) * 2002-05-24 2004-09-29 张志方 一种重组人b淋巴细胞刺激因子表达载体的构建、dna免疫制备单克隆抗体及其应用
RU2005141541A (ru) * 2003-06-05 2006-06-27 Дженентек, Инк. (Us) Комбинированная терапия в-клеточных нарушений
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
CN101851291B (zh) * 2010-02-09 2011-10-26 中国人民解放军第四军医大学 一种抗人baff单克隆抗体的重链和轻链可变区

Also Published As

Publication number Publication date
IN2014MN02367A (enExample) 2015-08-14
CN103421113B (zh) 2018-01-19
EP2853543A1 (en) 2015-04-01
CN103421113A (zh) 2013-12-04
BR112014025651A2 (pt) 2017-07-04
EP3792280A2 (en) 2021-03-17
US20150259409A1 (en) 2015-09-17
JP2015517505A (ja) 2015-06-22
EP3792280A3 (en) 2021-07-21
RU2014133410A (ru) 2016-07-10
EP2853543A4 (en) 2016-03-30
ZA201408955B (en) 2015-12-23
EP2853543B1 (en) 2020-09-02
RU2613422C2 (ru) 2017-03-16
US9828423B2 (en) 2017-11-28
WO2013174264A1 (zh) 2013-11-28
EP2853543A8 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
JP6006404B2 (ja) 抗ＢＬｙＳ抗体
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
TWI373343B (en) Antibodies that bind human interleukin-18 and methods of making and using
TWI307716B (en) Dual specificity antibodies and methods of making and using
CA2980087A1 (en) Antibodies to canine interleukin-4 receptor alpha
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
EP4317186A1 (en) Nanobody targeting bcma and application thereof
JP7755062B2 (ja) 新規抗ｌ１ｃａｍ抗体
WO2017182427A1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
WO2021098822A1 (zh) 一种双特异性抗体
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
CN110872349A (zh) 结合人il-4r的抗体、其制备方法和用途
WO2022228183A1 (zh) 抗siglec15抗体及其制备方法和用途
EP4660205A1 (en) Multiple antibodies against human il-36r and/or human il-1r3, and uses thereof
CN116209459A (zh) Il-10突变蛋白及其融合蛋白
WO2020119707A1 (zh) 抗il-17a抗体及其应用
TW202003854A (zh) 抗人ｌａｇ－３單克隆抗體及其應用
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
WO2021209066A1 (zh) 特异性抗原结合分子，其制备方法及医药用途
CN115947855B (zh) 抗cd24抗体的制备及其用途
CN114456267A (zh) 一种抗cd73人源化单克隆抗体及其应用
CN115785269B (zh) 抗pd-l1的抗体及其应用
CN117586390A (zh) 抗cgrp抗体及用途
CN110922483A (zh) 抗ccr5抗体及其在治疗肿瘤中的应用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160713

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160908

R150 Certificate of patent or registration of utility model

Ref document number: 6006404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250